Skip to main content
Top
Published in: Neurocritical Care 3/2013

01-06-2013 | Practical Pearl

Hashimoto’s Encephalopathy in the Intensive Care Unit

Authors: B. Chaigne, E. Mercier, D. Garot, A. Legras, P. F. Dequin, D. Perrotin

Published in: Neurocritical Care | Issue 3/2013

Login to get access

Abstract

Background

Since the first description of Hashimoto’s Encephalitis (HE) in 1966 by Lord Brain, the number of reported cases has continued to increase. In addition, cases of status epilepticus have been reported, suggesting a role for intensive care unit (ICU) practitioners in taking care of patients with HE.

Methods

A retrospective cohort study in ICU patients with HE was performed at the University Hospital of Tours, France.

Results

Eight HE cases were admitted to the ICU between 1/1/2000 and 1/1/2012. Herein, we describe the characteristics of the patients, with an emphasis on ICU disease management and its outcome.

Conclusion

ICU practitioners should be aware of this disease, since it can include life-threatening presentations.
Literature
1.
go back to reference Brain L, Jellinek EH, Ball K. Hashimoto’s disease and encephalopathy. Lancet. 1966;2(7462):512–4.PubMedCrossRef Brain L, Jellinek EH, Ball K. Hashimoto’s disease and encephalopathy. Lancet. 1966;2(7462):512–4.PubMedCrossRef
2.
go back to reference Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003;60(2):164–71.PubMedCrossRef Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003;60(2):164–71.PubMedCrossRef
3.
go back to reference Chaigne B, Beaufils E, Jouan Y, Magnant J, Maillot F, Constans T, et al. Hashimoto’s encephalopathy. Rev Med Interne. 2012;33(7):390–5.PubMedCrossRef Chaigne B, Beaufils E, Jouan Y, Magnant J, Maillot F, Constans T, et al. Hashimoto’s encephalopathy. Rev Med Interne. 2012;33(7):390–5.PubMedCrossRef
5.
go back to reference Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.PubMedCrossRef Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.PubMedCrossRef
6.
go back to reference Castillo P, Woodruff B, Caselli R, Vernino S, Lucchinetti C, Swanson J, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006;63(2):197–202.PubMedCrossRef Castillo P, Woodruff B, Caselli R, Vernino S, Lucchinetti C, Swanson J, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006;63(2):197–202.PubMedCrossRef
7.
go back to reference Marshall GA, Doyle JJ. Long-term treatment of Hashimoto’s encephalopathy. J Neuropsychiatry Clin Neurosci. 2006;18(1):14–20.PubMedCrossRef Marshall GA, Doyle JJ. Long-term treatment of Hashimoto’s encephalopathy. J Neuropsychiatry Clin Neurosci. 2006;18(1):14–20.PubMedCrossRef
8.
go back to reference Tamagno G, Celik Y, Simó R, Dihné M, Kimura K, Gelosa G, et al. Encephalopathy associated with autoimmune thyroid disease in patients with Graves’ disease: clinical manifestations, follow-up, and outcomes. BMC Neurol. 2010;10:27.PubMedCrossRef Tamagno G, Celik Y, Simó R, Dihné M, Kimura K, Gelosa G, et al. Encephalopathy associated with autoimmune thyroid disease in patients with Graves’ disease: clinical manifestations, follow-up, and outcomes. BMC Neurol. 2010;10:27.PubMedCrossRef
9.
go back to reference Archambeaud F, Galinat S, Regouby Y, Magy L, Rebeyrotte I, Vallat JM, et al. Hashimoto encephalopathy. Analysis of four case reports. Rev Med Interne. 2001;22(7):653–9.PubMedCrossRef Archambeaud F, Galinat S, Regouby Y, Magy L, Rebeyrotte I, Vallat JM, et al. Hashimoto encephalopathy. Analysis of four case reports. Rev Med Interne. 2001;22(7):653–9.PubMedCrossRef
10.
go back to reference Takahashi S, Mitamura R, Itoh Y, Suzuki N, Okuno A. Hashimoto encephalopathy: etiologic considerations. Pediatr Neurol. 1994;11(4):328–31.PubMedCrossRef Takahashi S, Mitamura R, Itoh Y, Suzuki N, Okuno A. Hashimoto encephalopathy: etiologic considerations. Pediatr Neurol. 1994;11(4):328–31.PubMedCrossRef
11.
go back to reference Zelaya AS, Stotts A, Nader S, Moreno CA. Antithyroid peroxidase antibodies in patients with high normal range thyroid stimulating hormone. Fam Med. 2010;42(2):111–5.PubMed Zelaya AS, Stotts A, Nader S, Moreno CA. Antithyroid peroxidase antibodies in patients with high normal range thyroid stimulating hormone. Fam Med. 2010;42(2):111–5.PubMed
12.
go back to reference Ferracci F, Moretto G, Candeago RM, Cimini N, Conte F, Gentile M, et al. Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto’s encephalopathy. Neurology. 2003;60(4):712–4.PubMedCrossRef Ferracci F, Moretto G, Candeago RM, Cimini N, Conte F, Gentile M, et al. Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto’s encephalopathy. Neurology. 2003;60(4):712–4.PubMedCrossRef
13.
go back to reference Fatourechi V. Hashimoto’s encephalopathy: myth or reality? An endocrinologist’s perspective. Best Pract Res Clin Endocrinol Metab. 2005;19(1):53–66.PubMedCrossRef Fatourechi V. Hashimoto’s encephalopathy: myth or reality? An endocrinologist’s perspective. Best Pract Res Clin Endocrinol Metab. 2005;19(1):53–66.PubMedCrossRef
Metadata
Title
Hashimoto’s Encephalopathy in the Intensive Care Unit
Authors
B. Chaigne
E. Mercier
D. Garot
A. Legras
P. F. Dequin
D. Perrotin
Publication date
01-06-2013
Publisher
Humana Press Inc
Published in
Neurocritical Care / Issue 3/2013
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-013-9834-1

Other articles of this Issue 3/2013

Neurocritical Care 3/2013 Go to the issue